Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#3966 PTK2 PROTAC unveiled as a selective inhibitor of gastrointestinal neuroendocrine cell proliferation via multi-target drug screening

Introduction: Gastrointestinal neuroendocrine tumors (GI-NETs) exhibit a complex and diverse nature, posing challenges in their effective treatment and management. While there have been advancements in treatment options, addressing the need for more effective and targeted therapies remains a significant issue, especially for patients with advanced or metastatic disease. Improving outcomes in the management of patients with GI-NETs is a key priority, and further research and development are crucial in this regard.

Conference:

Presenting Author: Gagliano T

Authors: Malavasi E, Toffoli L, Dainotto M, Gagliano T,

Keywords: Protac, PTK2, Screening, GI-NETs,

#3504 Telotristat ethyl affects crosstalk between tumor cells and stromal fibroblasts in small intestinal neuroendocrine tumors (SI-NETs)

Introduction: SI-NETs are often associated with mesenteric fibrosis (MF) which causes significant morbidity and mortality. Telotristat ethyl (TE) was developed to treat carcinoid syndrome in SI-NET patients however, recent studies indicated TE could also have anti-tumor activity, the mechanism for which remains unclear.

Conference:

Presenting Author:

Authors: Hodgetts H, Martins M, Chen L, Laskaratos F, Hall A,

Keywords: fibrosis, fibroblast, crosstalk, telotristat, intestine, small, tumor,

#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells

Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Refardt J

Authors: Refardt J, Klomp I, van Koetsveld P, Dogan-Oruç F, de Herder W,

Keywords: somatostatin type 2 receptor, BON-1, GOT-1, upregulation, DNA methyltransferase inhibitor, histone deacetylase inhibitor, epigenetic,